Jack S, Madhivanan K, Ramadesikan S, et al. - Researchers offered the foundation for a transformative anticancer strategy for bladder cancer that derives benefit from the unique features of the bladder. In view of the fact that cancer cells are exposed to the bladder lumen and overexpress EGFR unlike mucin-shielded normal bladder cells, they utilized an EGF-conjugated anthrax toxin that following targeting EGFR was internalized and initiated apoptosis in exposed bladder cancer cells. Compared with other EGF-based technologies and other toxin-derivatives, this unique agent afforded more benefits. Promotion of its own uptake through receptor microclustering even in the presence of Her2 and cell death with a LC₅₀ < 1 nM were both induced by this EGF-toxin conjugate, compared with known agents. Experts concluded that the basis for novel, transformative approaches against bladder cancer is afforded by this EGF–anthrax toxin conjugate as it displayed in vitro and in vivo high efficiency, fast action (decreasing treatment time from hours to minutes) and safety.